We read with interest the article “choroidal thickness changes after photodynamic therapy and recurrence of chronic central serous chorioretinopathy” by Kim and associates. They have reported long-term outcomes of chronic central serous chorioretinopathy (CSC) patients treated with either half-fluence or half-dose photodynamic therapy (PDT) in a well-designed study. They confirmed a well-known finding, “resolution of subfoveal choroidal thickening” after treatment in chronic CSC. Interestingly, they found choroidal thickness ratio (choroidal thickness at 1 month after treatment/choroidal thickness at baseline) to be a strong indicator of persistent or recurrent disease in the long term. This may really help clinicians and may modify follow-up schemes applied to these patients. Contrary to relatively quicker resolution of the subretinal fluid and associated thinning of the central retinal thickness, choroidal thinning took longer, which was related to remodeling of the choroidal vasculature by the authors of the current study. We wonder if the treatment effect goes beyond this remodeling process and may result in choroidal atrophy. The comparison of the final choroidal thickness measurements on both eyes of patients with unilateral disease would give an idea about this question. We would be keen to know if the authors can share their opinion.